Better understanding of the different mutations that drive GIST is leading to new paradigms of tailored treatment that break many norms of chemotherapy, especially in management of progression.
Related Articles
Impact Factor
Sunitinib versus interferon-á in metastatic RCC
Editorial
We don’t have to be a year behind
Impact Factor